Zymeworks Inc
ZYME
NASDAQ
Biotechnology
$25.12
USD
-0.64 (-2.48%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $1.79B
Volume 332.5K
Revenue
$37.13M
TTM
-69.8%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-149.99M
TTM
-103.6%
YoY
Operating Cash Flow
$-119.34M
TTM
-208.2%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 48.7 | 27.6 | 2.5 | 2.4 | 4.6 |
YoY Growth | +153.2% | +72.6% | -91.9% | -91.1% | -90.6% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 48.7 | 27.6 | 2.5 | 2.4 | 4.6 |
Selling, General & Administrative | 15.0 | 14.1 | 15.4 | 15.1 | 19.3 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 49.4 | 49.7 | 46.7 | 49.5 | 46.8 |
Operating Income | -0.7 | -22.1 | -44.2 | -47.1 | -42.2 |
EBITDA | 1.8 | -20.6 | -43.1 | -46.0 | -41.0 |
Other Income / Expense | -0.6 | 0.3 | -0.3 | 0.1 | 0.2 |
Total Other Income / Expense | 2.8 | 3.8 | 2.7 | 0.8 | -3.1 |
Income Before Income Taxes | 2.1 | -18.3 | -41.5 | -46.4 | -45.3 |
Income Taxes | -0.2 | 1.3 | -0.3 | -2.2 | -0.3 |
Net Income | 2.3 | -19.6 | -41.2 | -44.2 | -45.0 |
Consolidated Net Income / Loss | 2.3 | -19.6 | -41.2 | -44.2 | -45.0 |
Net Income Attributable to Common Shareholders | 2.3 | -19.6 | -41.2 | -44.2 | -45.0 |
Basic EPS | $0.03 | -$0.26 | -$0.55 | -$0.59 | -$0.62 |
Diluted EPS | $0.03 | -$0.26 | -$0.56 | -$0.59 | -$0.62 |
Basic Shares Outstanding | 75.3M | 75.8M | 75.3M | 74.7M | 73.0M |
Diluted Shares Outstanding | 77.4M | 75.8M | 73.3M | 74.7M | 73.0M |